US 12,343,374 B2
Enhancement of antibacterial actions of a depsipeptide antibiotic using synergistic amounts of boric acid
Jerome J. Schentag, Buffalo, NY (US); and Hirofumi Nakajima, Kobe (JP)
Assigned to KYOTO BIOPHARMACEUTICALS, INC., Kyoto (JP)
Appl. No. 17/251,367
Filed by KYOTO BIOPHARMACEUTICALS, INC, Kyoto (JP)
PCT Filed Jun. 12, 2019, PCT No. PCT/IB2019/054921
§ 371(c)(1), (2) Date Dec. 11, 2020,
PCT Pub. No. WO2019/239352, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/684,316, filed on Jun. 13, 2018.
Prior Publication US 2021/0244790 A1, Aug. 12, 2021
Int. Cl. A61K 38/15 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 33/22 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/38 (2006.01); A61P 31/04 (2006.01)
CPC A61K 38/15 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 33/22 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/38 (2013.01); A61P 31/04 (2018.01)] 15 Claims
 
1. An antimicrobial composition formulated for external use in prevention or treatment of a gram positive bacterial infection, comprising lotilibcin having the following chemical structure (1):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof in a concentration of at least 0.03 μg/mL in combination with boric acid in an amount of at least 0.01% by mass, wherein said combination exhibits synergistic antibacterial activity.